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KEY MESSAGES
 Placebo prescription is frequent in northern Portugal, especially among younger GPs.
 GPs with higher empathy scores are more favourable to placebo prescription.
ABSTRACT
Background: Empathy in the patient–physician relationship is a major component in an effective
placebo treatment, as in every medical treatment. Understanding the role of empathy of the
physician in the placebo effect may help dissect some of the context variables responsible for
the effectiveness of the placebo.
Objectives: To determine the frequency of placebo prescription, doctors’ beliefs, motivation, and
attitudes to placebos in general practice in northern Portugal and to test the association
between placebo prescription and physician empathy.
Methods: A cross-sectional study was conducted between November 2014 and January 2015
among general practice specialists and interns from 14 health centres in a northern Portuguese
health region. The self-report questionnaire included the Portuguese version of the Jefferson
scale of physician empathy (JSPE) and a questionnaire about placebo prescription. Associations
between demographic variables, JSPE score, prescription of placebo, and the attitudes to pla-
cebo score were tested with the chi-squared statistic, student t-tests for independent samples,
and Pearson correlation.
Results: The study included 93 general practitioners (GP) (response rate: 74%). Placebos were
prescribed by 73% (n¼ 68) of the respondents. GPs who prescribe placebo are significantly
younger (mean age¼ 38.4 years; SD¼ 11.1; t (90)¼ 2.98, P<.05, d¼ 0.67) than non-prescribers
(mean age ¼46.5 years; SD ¼13.3). Favourable attitudes towards placebo prescription are associ-
ated with higher empathy scores (R¼ 0.310, P<.01).
Conclusion: Placebo prescription is frequent and associated with empathy from the prescriber,
especially among younger GPs.
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Introduction
The effectiveness of most medical interventions par-
tially relies on contextual or subjective factors, aside
from the tangible and objective treatment methods
already established and used in medicine [1]. Thus,
empathy, as a critical factor in the clinical context, has
been found to positively affect outcomes of both pla-
cebo treatments and bioactive treatments [2]. It has
become clear that placebo responses derive not only
from the belief that a bioactive compound was admin-
istered or that a legitimate medical procedure was
undergone but also from environmental and psycho-
social factors embedded within clinical and research
encounters [3]. Nonetheless, most placebo research has
been focused on understanding the underlying neuro-
biological mechanisms of the patient’s response to pla-
cebos, and less on understanding the physician
component of the clinical dyad [4].
Recent evidence suggests that medical providers
use placebo treatments widely, and even that patients
can be open for those interventions under certain cir-
cumstances [5–7]. Among primary healthcare, although
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the extent of this practice is highly variable, inter-
national retrospective studies report figures ranging
from 17% to 99% of general practitioners (GP) using pla-
cebo treatments at least once in their career [5]. The dis-
tinctive features of general practice, where clinicians see
patients with a wide variety of complaints and symp-
toms, serving unselected populations, with diagnostic
uncertainty, pressure to treat, and time constraints,
make placebo prescription a frequent option [5].
As a psychobiological process, the placebo effect is
due to the therapeutic context, including the patient,
the physician, and their interaction with the surround-
ing environment [8]. Previous research stresses the
importance of the healing context for therapeutic
effect and the placebo effect. Both rely on expecta-
tions, conceptions, and prejudices as factors that pro-
mote or compromise the healing process [9]. In one
representative study of irritable bowel syndrome, the
positive effects of placebo acupuncture were
enhanced if promoted by an empathic physician [2].
This emphasizes the role of empathy as a major com-
ponent of the doctor–patient relationship and the
healing process, contributing as an important factor to
the placebo effect.
Despite the potential role of empathy, there are no
studies exploring the relationship between physician
empathy and attitudes, beliefs, and practices regarding
placebo prescription. The objectives of this study were
to determine the extent of placebo prescription by
GPs in one region and test the associations between
placebo prescription and physician empathy.
Methods
Study design
The study population consisted of specialist GPs and
second, third and fourth-year GP interns in the 14
health centres of Matosinhos local health unit (MLHU),
an urban area in northern Portugal. First-year GP interns
were excluded from the study because they are not
licensed to prescribe medication. One of the 14 health
centres failed to reply to the request for participation
and was excluded from the study. Questionnaires on
placebo prescription were distributed in the health
centres between November 2014 and January 2015.
Ethics
Ethical approval for this study was obtained from the
University of Minho Life Sciences Ethics Committee
(Document SECVS 145/2014) and the MLHU Ethics
Committee (reference 079/CE/JAS).
Questionnaires
A self-reported anonymous questionnaire composed of
two sections was used. The first section assessed the
frequency and circumstances of placebo prescription,
providing a working definition of placebos to stand-
ardize interpretations adapted from other international
studies on this subject [10–13]. The questionnaire is
provided in Supplementary material (available online).
The second section consisted of the validated
Portuguese version of the Jefferson scale of physician
empathy (JSPE) [14,15]. The (JSPE) is an instrument
developed to measure empathy in physicians and
medical students and has been found to be valid in
some settings [15].
To assess the time required for completion of the
forms, face validity, and comprehension, the question-
naire was tested in a pilot study with six GPs from the
target population who were excluded from the final
study.
Statistical analysis
Statistical analyses were conducted considering the
variables measurement level. Assumptions for all tests
were considered. To test the normality of the distribu-
tion of scale variables, Kolmogorov–Smirnov (KS) tests
were conducted. When KS tests were statistically sig-
nificant, we used the following rules-of-thumb: abso-
lute skewness and kurtosis values lower than 3.0 and
8.0, respectively, and results did not show significant
diversion from a normal distribution [16]. Group differ-
ences were tested through chi-square independence
tests and student t-tests for independent samples
depending on variables measurement level. The
strength of association between two scale variables
was determined by Pearson correlation coefficients. An
exploratory factor analysis was conducted with the
questionnaire items evaluating attitudes towards pla-
cebo use. Internal consistency of the dimension of atti-
tudes towards placebo prescription and of the JSPE
subscales and total score were determined by
Cronbach’s alpha. Statistical analyses were conducted
using IBM-SPSS StatisticsVR (version 22). P-values <.05
were considered significant and effect sizes were inter-
preted according to values given by Cohen (1988) [17].
Results
Sample
From the 126 questionnaires initially distributed, a
gender and age representative sample of 93 GPs
(response rate: 74%) was obtained. Table 1 presents
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the demographics of the study sample. The mean age
of participants was 41 years, with a mean of 14 years’
seniority and 80% of the physicians were female.
Placebo prescription
Of the surveyed GPs, 73% (n¼ 68) prescribed placebos.
When asked about the frequency with which they pre-
scribed placebos, 43% (n¼ 29) reported doing so sev-
eral times a year, 34% several times a month, 10%
(n¼ 7) several times a week, and 3% (n¼ 2) prescribed
placebos several times a day. Ten per cent (n¼ 7) of
the GPs did not know how often they prescribed pla-
cebos or ignored the question.
Associations between demographic variables and
placebo prescription were tested (Table 2). A significant
association was found between age and placebo pre-
scription. Younger GPs (mean age¼ 38.4 years;
SD¼ 11.1) were more likely to be prescribers than older
GPs who were non-prescribers (mean age¼ 46.5 years;
DP¼ 13.3), t (90)¼ 2.98, P.05, two-tailed, d¼ 0.67).
GPs with fewer years of clinical practice (mean
seniority¼ 13.8 years; SD¼ 11.4) were more likely to be
placebo prescribers, than more experienced GPs (mean
seniority¼ 20.4 years; SD¼ 13.9; t (36.4)¼ 2.13, P .05,
two-tailed, d¼ 0.51). The effect sizes (Cohen’s d¼ 0.67
and 0.51, respectively) suggest a moderate to
high practical significance of the results. No associations
were found between gender and placebo prescription.
Patient information
The ways GPs inform patients about placebo prescrip-
tion varied. Many GPs, 43% (n¼ 29) say nothing to the
patient about this, 34% (n¼ 23) stated that the pre-
scription is a medicine without specific effects on the
patient’s ailment, 3% (n¼ 2) state that the prescription
is a medicine, and 10% (n¼ 7) state directly to the
patient that the prescription is a placebo.
Motivations for placebo prescription
The motivations reported by the GPs to justify placebo
prescription are shown in Table 3. The options ‘to
calm the patient’ (60%, n¼ 41), and ‘as a diagnostic
tool (to distinguish between real and imaginary symp-
toms or organic and psychological symptoms)’ (60%,
n¼ 41), were the most common justifications given for
placebo prescription.
Perception of placebo efficacy
Many GPs, 43% (n¼ 29), stated that the placebos pre-
scribed are ‘frequently’ effective, 34% (n¼ 23) stated
placebos are ‘sometimes’ effective, 10% (n¼ 7) consid-
ered that placebos are ‘never’effective and, 3% (n¼ 2)
claimed to ignore the efficacy of the placebos
prescribed.
Attitudes towards placebo prescription
The participants were asked to provide a semi-quanti-
tative evaluation of agreement with seven statements
about ethical and professional components of placebo
prescription on a seven-item Likert-type scale
(Table 4). Most GPs believe their patients could benefit
from placebos and are favourable to the prescription
of placebos as a therapeutic tool. Clinical practice and
scientific evidence of placebo effectiveness are import-
ant factors to consider when prescribing placebos. The
item that most divided opinions among GPs was the
need for prior informed consent. The results were con-
cordant when responses to statements regarding the
ethics of placebo prescription and prohibition of pla-
cebo prescription were compared. Most GPs who dis-
agreed with the statement that placebo prescription is
Table 2. Relations between placebo prescription and sociodemographic characteristics.
Prescribes placebo
Yes No P Effect size
Gender (n)
Female 73% (54) 27% (30) >.2 U¼ –0.006
Male 73% (14) 26% (5)
Seniority (n)
GP Specialist 72% (52) 27% (20) >.2 U¼ –0.037
GP Intern 76% (16) 23% (5)
Age (years; mean ± SD) 38.4 ± 11.1 46.5 ± 13.3 <.01 d¼ 0.67
Years of clinical practice (mean± SD) 13.8 ± 11.4 20.4 ± 13.9 <.05 d¼ 0.51
GP, general practitioner; SD, standard deviation.
Table 1. Demographic characteristics of general practitioners
included in the study.
Age (years; mean ± SD) 41 ± 12
Female (n) 80% (74)
Seniority (n)
GP specialist 77% (72)
General practice intern 23% (21)
Years of clinical practice (mean ± SD) 16 ± 12
SD, standard deviation.
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unethical also disagreed with the statement that pla-
cebo prescription should be prohibited.
Exploratory factor analysis (EFA) with principal com-
ponents method of factor extraction was conducted
with the items evaluating attitudes towards placebo
prescription (Supplementary material: Table S1). Items
6a and 6d (‘allowed if clinical practice corroborates
efficacy’ and ‘allowed after informed consent’) were
excluded for low communality (<0.5) and a new EFA
was conducted, revealing a unifactorial structure,
named score of attitudes towards placebo prescription
(SATPP, Cronbach’s alpha¼ 0.751). Results from tests
of item saturation were satisfying, as well as internal
consistency [18].
Jefferson scale of physician empathy
From the 93 questionnaires, only 88 JSPE question-
naires were correctly completed. Total scores of the
JSPE showed a good internal consistency (20 items,
Cronbach’s alpha¼ 0.804). The three dimensions of the
JSPE, perspective taking (PT, 10 items), empathic care
(EC, 7 items) and, standing in patient’s shoes (SPS,
three items) showed acceptable internal consistency
(PT, a¼ 0.655, item 18 excluded) and good internal
consistency (EC, a¼ 0.780; SPS, a¼ 0.718) [18].
Cross-tabulations (Table 5) reveal that higher scores
on the empathic care dimension of JSPE are signifi-
cantly associated with placebo prescribers (M¼ 64,
SD¼ 6, t (86)¼ 2.038, P¼ .045) than non-prescribers
(M¼ 61, SD¼ 9). More favourable attitudes towards
placebo prescription, measured by SATPP, are
significantly associated with higher JSPE total scores
(Pearson’s r (87)¼ 0.310, P¼ .003) and in perspective
taking (Pearson’s r (88)¼ 0.219, P¼ .041) and empathic
care (Pearson’s r (88)¼ .293, P¼ .006). Being a GP
intern is also associated with higher scores of
empathic care (M¼ 65, SD¼ 5, t (86)¼1.983,
P¼ .052) than senior GPs (M¼ 63, SD¼ 8). No signifi-
cant association was found between gender, age and
JSPE scores and dimensions.
Discussion
Main findings
This study among 93 Portuguese GPs provides the first
evidence for the extent of placebo prescription in gen-
eral practice in Portugal. Seventy-three per cent of
them admit prescribing placebos with varying fre-
quency. The circumstances of placebo prescription var-
ied. It is prescribed most often as a diagnostic tool to
distinguish real from imaginary symptoms, to appease
the patient, and as a treatment for nonspecific symp-
toms. The perception of the efficacy of placebos is
high and many GPs do not explain to the patient that
they are prescribing a placebo.
Strengths and limitations
The definition of placebo and measures of frequency
of prescription vary significantly between studies mak-
ing comparisons difficult. However, it is evident that
placebo prescription in northern Portugal is frequent,
particularly among younger GPs and interns. In the
Table 3. Motivations for placebo prescription among northern Portuguese GPs (n¼ 68).
In which situations would/did you prescribe a placebo? (n)
As a diagnostic tool (to distinguish between real and imaginary symptoms, or organic and psychological symptoms) 60% (41)
To calm a patient 60% (41)
As a treatment for an unspecific symptom 47% (32)
To appease a complaining patient 46% (31)
As a substitute for a medicine without rationale but the patient expected it 38% (26)
As a supplement for other medicine 37% (25)
As a substitute while titrating the dose of a medicine (e.g. psychotropic medication withdrawal) 21% (14)
For pain control 15% (10)
Table 4. Attitudes and ethical considerations towards placebo prescription. Results of the seven-item Likert scale
survey assessing attitudes towards placebo prescription.
Regarding placebo prescription, how much do you agree/disagree with the following statements? Score (mean± SD) Agreementa
My position about placebo prescription is that it should be:
Always forbidden. 2.4 ± 1.4 7%
Allowed if scientific data of efficacy exists. 5.0 ± 1.6 66%
Allowed if my clinical experience supports efficacy. 4.4 ± 1.6 54%
Allowed after informed consent. 4.0 ± 2.0 40%
I consider that my patients could benefit from placebos. 4.7 ± 1.5 60%
I consider that placebo prescription could be included in the therapeutic arsenal. 4.6 ± 1.6 58%
I consider placebo prescription ethically reprehensible. 2.3 ± 1.3 7%
aCumulative frequencies of Likert scale 4 to 7.
SD, standard deviation.
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only study where (pure) placebo prescription was eval-
uated among interns (in internal medicine), 16% of the
respondents claimed to have already prescribed pla-
cebos, while in the current study 76% of GP interns
claim to have done so [19]. This difference may be
due to the inclusion of impure placebos in the defin-
ition of placebos in the current study and the fact that
the two studies assessed different medical specialties.
This study enrolled 126 GPs and interns from 14
health centres, representative of one Portuguese
health region, and obtained a good response rate.
Even though this may not be representative of all
Portuguese GPs and the findings may reflect selection
bias, it provides a first clear look at placebo prescrip-
tion in Portugal.
There are no validated questionnaires in Portuguese
regarding placebo prescription and circumstances of
placebo prescription in clinical practice. The question-
naire used could benefit from further validation.
Comparison with existing literature
The main results of this study are consistent with pre-
viously published findings, where the proportion of
placebo prescription ranged from 17% to 99% of GPs
[5,13]. Thirty-four per cent of GPs in this study claim to
prescribe placebos several times a month and, 43%
claim to prescribe them several times a year. In other
studies, wide variability in frequency was noted. For
example, 45% of German GPs prescribe placebos at
least once per year, and 38% of Danish GPs prescribe
1 to 10 times per year [13,20].
Placebo prescription is a controversial subject,
which required this study to address the ethical and
professional issues involved in a broad manner
(Table 4). Although most GPs in this study were
against the prohibition of placebos (75%) and do not
consider it ethically wrong (81%), there were still 25%
of GPs who disagree with the prescription of placebos
in medical care. Furthermore, from the 27% of GPs
who do not prescribe placebos, only 7% feel this
should be prohibited. The reasons for this behaviour
are probably linked to deontological constraints
involved in the act of prescribing a placebo given that
there is an ethical and legal obligation for telling the
truth to patients, and because the use of placebo is
only legally sanctioned in research when subjects give
informed consent [21].
There were no published studies found testing the
associations between empathy and placebo prescrip-
tion. In this study, we demonstrated a significant asso-
ciation between placebo prescription and higher
scores of empathy measured by the JSPE. Moreover,
favourable attitudes towards placebo prescription,
summarized in the attitudes score we generated (the
SATPP), were associated with higher scores on the
JSPE and two of its dimensions, empathic care and
perspective taking.
In some studies, a decline in empathy was observed
among medical students during their training [22].
Attitudes and beliefs toward placebo prescription may
Table 5. Associations between empathy (JSPE) results, placebo prescription and demographic characteristics
Total JSPE score
(mean± SD)
Perspective taking
(mean± SD)
Empathic care
(mean± SD)
Standing in patient’s shoes
(mean ± SD)
Prescribes placebo
Yes 120 ± 11 38 ± 4 64 ± 6 17 ± 3
No 115 ± 15 38 ± 5 61 ± 9 16 ± 4
P 0.111 0.788 0.045 0.356
D 0.380 0 0.392 0.283
SATPP
P 0.003 0.041 0.006 0.085
R 0.310 0.219 0.293 0.186
Status
Specialist GP 118 ± 13 38 ± 5 63 ± 8 17 ± 3
GP intern 121 ± 8 39 ± 3 65 ± 5 16 ± 3
P 0.329 0.413 0.052 0.365
D –0.278 –0.243 –0.300 0.333
Gender
Female 117 ± 13 38 ± 3 63 ± 7 17 ± 3
Male 119 ± 12 38 ± 5 62 ± 8 17 ± 4
P 0.563 0.582 0.564 0.942
D –0.160 0 0.133 0
Age
P 0.563 0.325 0.202 0.533
R –0.063 0.107 –0.138 –0.068
JSPE, Jefferson scale of physician empathy; SATPP, score of attitudes towards placebo prescription.
Measures of effect size: r¼ Pearson correlation Coefficient; D¼ Cohen’s d.
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also change during medical education [23]. However,
we cannot elaborate if changes in empathy are associ-
ated with changes in attitudes towards placebo pre-
scription over time. This might be clarified in
longitudinal studies.
Implications for clinical practice and research
Since empathy is a crucial element in the healing con-
text, this study was designed to test the association
between placebo prescription and empathy of the pre-
scribing physician. These findings may help us under-
stand why placebos are effective and what are the
context conditions responsible for its effect, dissecting
the science of placebo and enabling the physician to
harness the contextual factors and the conditions that
promote a beneficial healing environment.
Due to ethical and professional constraints, the
exact extent of placebo prescription is difficult to
assess and will remain controversial in the medical
community and among the public. Prospective studies
with the debriefing of physicians to understand their
prescribing choices may contribute to clarify this issue
further.
The results from this study suggest that education
of medical students and interns is necessary to raise
awareness about placebos and in forming opinions
about their ethical use. The inclusion of the topic of
placebo prescription in the medicine schools’ curricula
may improve decision making of future doctors when
facing this subject.
Conclusion
Placebo prescription is frequent among GPs in north-
ern Portugal and most frequent among younger GPs.
Empathy of the GPs is associated with openness to
placebo prescription. Our results come from a narrow
geographic area and may need to be repeated in
other regions. However, it seems clear that a wider
debate about placebo prescription in clinical practice,
including therapeutic, legal and ethical aspects is
required.
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